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ConsensusAbstract The primary treatment of pancreatic cancer was the topic of the 3rd St. Gallen
Conference 2016. A multidisciplinary panel reviewed the current evidence and discussed
controversial issues in a moderated consensus session. Here we report on the key expert rec-
ommendations.
It was generally accepted that radical surgical resection followed by adjuvant chemotherapy
offers the only evidence-based treatment with a chance for cure. Initial staging should classify
localised tumours as resectable or unresectable (i.e. locally advanced pancreatic cancer)
although there remains a large grey-zone of potentially resectable disease between these two
categories which has recently been named as borderline resectable, a concept which was gener-
ally accepted by the panel members. However, the definition of these borderline-resectable
(BR) tumours varies between classifications due to their focus on either (i) technical hurdles
(e.g. the feasibility of vascular resection) or (ii) oncological outcome (e.g. predicting the risk
of a R1 resection and/or occult metastases).
The resulting expert discussion focussed on imaging standards as well as the value of pre-
therapeutic laparoscopy. Indications for biliary drainage were seen especially before neoadju-
vant therapy. Following standard resection, the panel unanimously voted for the use of
adjuvant chemotherapy after R0 resection and considered it as a reasonable standard of care
after R1 resection, even though the optimal pathologic evaluation and the definition of R0/R1
was the issue of an ongoing debate.
The general concept of BR tumours was considered as a good basis to select patients for
preoperative therapy, albeit its current impact on the therapeutic strategy was far less clear.
Main focus of the conference was to discuss the limits of surgical resection and to identify
ways to standardise procedures and to improve curative outcome, including adjuvant and
perioperative treatment.
ª 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The main topic of the 3rd St. Gallen European Orga-
nisation for Research and Treatment of Cancer
Gastrointestinal Cancer Conference 2016 was the pri-
mary treatment of pancreatic cancer. Ductal adeno-
carcinoma of the pancreas is one of the most common
causes of cancer-related death worldwide. Predictions
for 2025 rank pancreatic cancer as the third-leading
cause of cancer-related death in the European Union
[1] and by 2030 as the second-leading cause of cancer-
related death in both genders in the United States of
America [2]. Prognosis is dismal with a life expectancy
below 5% after 5 years [3]. The only proven chance for
increased long-term survival or even cure consists in
radical surgical resection followed by adjuvant
chemotherapy [4,5]. However, less than 20% of thepatients present with a localised tumour that is clearly
resectable at the outset. Initial staging is used to clas-
sify localised pancreatic cancer as resectable or unre-
sectable (locally advanced pancreatic cancer [LAPC])
with a large grey-zone of potentially resectable tu-
mours between these two categories, which has led to
the identification of a third category, the so-called
borderline-resectable (BR) tumours. However, defini-
tion varies between different classification systems due
to their focus on either technical hurdles (e.g. vascular
resection) or oncological outcomes (e.g. predicted R1
resection) [6e10]. Therefore, the main focus of this
conference was to discuss the limits of surgical resec-
tion and to identify ways to improve out-
comedincluding optimised planning of the therapeutic
strategy, more advanced surgical techniques as well as
adjuvant or perioperative treatments.
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and radiation oncologists, pathologists and gastroen-
terologists reviewed the current treatment recommen-
dations in a panel session based on a moderated
consensus process. The main interests were controversial
issues that could not be easily resolved through the
study of published evidence and guidelines. As in the St.
Gallen Breast Cancer Conferences, the panel was asked
to assess the available evidence and vote on recom-
mendations using a pre-circulated set of questions. Here,
we summarise the key discussion points of the panel
members.2. Methods
In preparation for the panel session, which was held on
12th March 2016 and involved 18 experts, existing
guidelines [7,8,11,12] were used to identify areas of un-
certainty in order to define the topics for debate. Over
100 questions were circulated between panel members,
of which 68 were retained for the panel discussion.
During the session, which was moderated by JZ and ML
the panel members were asked to assess and comment
on optimal care based on the existing data and to
recommend treatment strategies as expert opinion.
Panel members were given the opportunity to comment
on the issues raised by the questions before and after an
electronic vote. Here, we summarise the extent of
agreement or disagreement of the panel members on
specific topics.
Even though care was taken to invite a representative
spectrum of panellists from relevant disciplines, the
general applicability of their conclusions may be limited
by an unequal distribution of disciplines and/or under-
representation of some regions of the world (all panelists
are co-authors). The ensuing statements are generally
meant for reasonably fit patients without severe
comorbidities. In clinical practice, some patients will not
match the model and treatment decisions need to be
adapted.3. Staging
Accurate pretherapeutic imaging of the primary tumour
is the key component of any treatment decision [13], in
addition to the full assessment of the patient’s clinical
status, comorbidities as well as screening for distant
metastases. Resectability and the surgical approach
depend on tumour size and location, anddmost
importantlydis limited by involvement of regional
blood vessels. Arterial abutment or venous occlusion
not only have a technical impact on the surgical
approach and the complication rate, but also affect
prognosis [10].
For primary visualisation of the tumour, a dedicated
pancreatic protocol computed tomography (CT) scanwith submillimetre sections was chosen as the preferred
method by most panel members (92%), with only 8%
opting for mandatory magnetic resonance imaging
(MRI) and/or endoscopic ultrasonography (EUS).
To evaluate the potential for resection, a dedicated
multiphase pancreatic CT scan was unanimously voted
as the preferred diagnostic method (100%), with no need
for a second imaging modality if the tumour and the
surrounding vessels were visualised appropriately (92%).
If needed, MRI was preferred over EUS (75%
versus 25%) as the additional imaging method. Image
acquisition has to be performed carefully within a
defined multiphase protocol with high resolution. The
imaging report should follow the recently published
consensus recommendations [13] (Table 1).
Routine laparoscopic staging in resectable cancer was
not considered necessary by all but one of the panel
members. However, laparoscopy would be performed
by 38% of the panelists in patients with BR tumours, by
1/3 of the panel in patients with risk factors (e.g. pain or
grossly elevated CA 19-9 levels potentially indicating
subradiographic systemic disease [14e16]) and by 14%
in all patients with left-sided tumours in the pancreatic
tail or body because of the increased risk of peritoneal
seeding in this population [17]. Thirty-eight percent
would also perform laparoscopy before any neo-
adjuvant treatment, again with the aim to exclude
peritoneal disease before starting multimodal therapy.
Peritoneal lavage was deemed of no use by almost all
panellists (94%), mainly because most (77%) would not
change their surgical approach based on positive
cytology alone.
Complete staging includes the search for distant
metastases in liver and lung. Staging for lung metas-
tases is preferably performed by CT scan (90%) and not
by chest X-ray (0%). Imaging of the liver is usually
included in the staging CT of the primary tumour with
no need for an additional MRI (only 18% were in
favour of an additional scan) and no role for ultraso-
nography (voted as ‘not sufficient’ by 62% with 38%
abstentions). There was also no role for positron-
emission tomographyeCT (82%). If CT demonstrates
‘small pulmonary nodules’, virtually all panel members
would neglect them if they are smaller than 5 mm
(93%). Fifty seven percent would even neglect those
that are smaller than 10 mm, a view supported by two
retrospective series from the US using preoperative
chest CT scans and clinical follow up of 374 and 329
patients, respectively. Indeterminate pulmonary nod-
ules (IPN) [18] or subcentimeter pulmonary nodules
(SCPN) [19] were detected in 49% and 18% of the scans
with no statistically relevant difference in median
overall survival (15.6 months with IPN versus 18.0
months without IPN and 16.1 months with SCPM
versus 19.1 months without SCPN). IPN also had no
significant impact on the rate of subsequent develop-
ment of lung metastases (16% versus 13%). In fact, only
Table 1
Technical requirements, interpretation and reporting of pretherapeutic dedicated multidetector CT in pancreatic cancer.
Technical parameters (dedicated dual-phase pancreatic protocol with angiography)
Scan type Helical (preferably at least 16-detector rows)
Section thickness Preferably submillimeter (0.5e1 mm)
Interval Same as section thickness
Oral contrast agent Neutral or low-Hounsfield units oral agent
Intravenous contrast agent Preferably high iodine concentration, injection rate of 3e5 ml/s
Scan acquisition - Pancreatic parenchymal phase at 40e50 s (shortly after arterial phase)
- Portal venous phase at 65e70 s
Image reconstruction - Axial 2e5 mm thickness
- Multiplanar reformats in the coronal plane at 2e3 mm thickness (per institutional
preference additional sagittal plane)
- Maximum intensity projections or 3D volumetric thick sections for vascular evaluation
Morphologic evaluation
Appearance - Hypoattenuating, isoattenuating or hyperattenuating (in the pancreatic parenchymal phase)
- Size
- Location (head/uncinated or body/tail)
Pancreatic duct Narrowing/abrupt cut-off with or without dilatation
Biliary tree Abrupt cut-off with or without upstream dilatation
Arterial evaluation
Superior mesenteric artery (SMA) Present or absent
- Degree of solid soft-tissue contact (180 or >180)
- Degree of increased hazy attenuation/stranding contact (180 or >180)
- Focal vessel narrowing or contour irregularity (extension to first SMA branch?)
Celiac axis Present or absent
- Degree of solid soft-tissue contact (180 or >180)
- Degree of increased hazy attenuation/stranding contact (180 or >180)
- Focal vessel narrowing or contour irregularity (present?)
Common hepatic artery (CHA) Present or absent
- Degree of solid soft-tissue contact (180 or >180)
- Degree of increased hazy attenuation/stranding contact (180 or >180)
- Focal vessel narrowing or contour irregularity (present?) (Extension to celiac axis or bifurcation
of right/left hepatic artery?)
Arterial variant Present or absent
- Variant anatomy (accessory right hepatic artery, replaced right hepatic artery, replaced
CHA, origin of replaced or accessory artery, others)
- Degree of solid soft-tissue contact (180 or >180)
- Degree of increased hazy attenuation/stranding contact (180 or >180)
- Focal vessel narrowing or contour irregularity (present?)
Venous evaluation
Portal vein (MPV) Present, absent or complete occlusion
- Degree of solid soft-tissue contact (180 or >180)
- Degree of increased hazy attenuation/stranding contact (180 or >180)
- Focal vessel narrowing or contour irregularity (tethering or tear-drop?)
Superior mesenteric vein (SMV) Present, absent or complete occlusion
- Degree of solid soft-tissue contact (180 or >180)
- Degree of increased hazy attenuation/stranding contact (180 or >180)
- Focal vessel narrowing or contour irregularity (tethering or tear-drop?)
Thrombus within vein Present or absent (MPV, SMV or splenic vein)
Venous collaterals Present or absent (location: around pancreatic head, porta hepatis, root of the mesentery or left
upper quadrant)
Adapted from the Consensus Statement of the Society of Abdominal Radiology and the American Pancreatic Association (Radiology 270;
1:248e260, 2014)
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individual radiographic criterion of SCPN including
number, size, calcification or contour had an impact on
overall survival [19].
Of note, the discussion did not cover the imaging
strategy within surveillance programmes for early
detection of pancreatic cancer in individuals at increasedrisk which has been the topic of several recent publica-
tions [20e22].
4. Pretherapeutic bile-duct drainage
In patients with bile duct obstruction, placement of a
biliary stent via endoscopy may be used to relieve
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tions and a significantly increased risk of bacterial
cholangitis [23] that might have a negative impact on the
success of surgery [24].
Therefore, the majority of the panel (54%) felt that
biliary drainage before primary surgery should generally
be avoided and restricted to patients with signs of
cholangitis or even to patients with cholangitis and
grossly elevated bilirubin levels only. Most panel mem-
bers (81%) would even avoid a stent altogether if tumour
resection was possible within one week.
Prior to preoperative multimodal therapy stent
placement was deemed useful in cholangitis, but not
necessarily in patients with simple cholestasis and no
signs of infection (64% pro drainage in all patients).
Some additional 18% of the panellists would be more
restrictive and place stents only if bilirubin levels were
grossly elevated (10  upper limit of normal (ULN)). In
any case, bilirubin levels should be lowered to 1.5 
ULN if preoperative FOLFIRINOX is to be given.
The preferred type of stent is a short metal stent (54%
versus 46% for a plastic stent) which is more expensive
but has the potential for longer patency, a lower risk of
cholangitis interfering with neoadjuvant treatment
anddif short enoughdcan easily be removed during
resection [25,26].
5. Adjuvant treatment
Removal of the primary tumour without any additional
treatment results in 5 year survival rates of 8e12%
[4,27,28]. Several randomised phase III trials [27e29]
have shown that additional postoperative chemo-
therapy (CTx) after macroscopically complete resection
(i.e. R0 and R1) with either gemcitabine or 5-FU
consistently increases 5-year survival by at least 11%
(up to 24.4% in one trial). In contrast, results with
postoperative radiochemotherapy (RCTx) vary between
trials, with some reports even suggesting a deleterious
effect [30,31].
Final results of the multicentre randomised phase III
ESPAC-4 trial were published by Neoptolemos et al. [32]
shortly after the St. Gallen conference, demonstrating a
further increase in median overall survival from 25.5
months in the gemcitabine arm to 28 months with a
combination regimen of gemcitabine and the oral fluo-
ropyrimidine capecitabine (hazard ratio (HR) 0.82, 95%
confidence interval (CI) 0.68e0.98, p Z 0.032). The 5-
year survival estimates increased from 16.3% (95% CI
10.2e23.7) for patients randomised to gemcitabine to
28.8% (22.9e35.2) with gemcitabine/capecitabine.
Similar to previous trials, patients with R0 resections had
better survival and significant benefit from combination
treatment whereas the survival benefit formargin positive
tumours did not reach significance.
The panel unanimously (100%) voted for the use of
adjuvant chemotherapy (CTx) after R0 resection, withno role for simultaneous RCTx or sequential CTx/
RCTx. Gemcitabine was chosen as preferred CTx
regimen (73%), with minority votes for the use of 5-FU/
leucovorin, FOLFIRINOX or gemcitabine/Nab-
paclitaxel. The same holds true after R1 resection
(80% were in favour of CTx). Please note, that this vote
most likely would have been influenced by the positive
results of the ESPAC-4 trial cited above which are in
favour of the combination of gemcitabine and the orally
active 5-FU derivative capecitabine [32] but had not yet
been available during the conference. Also, whereas
gemcitabine, 5-FU and gemcitabine/capecitabine have
all been successfully investigated as adjuvant treatment
in phase III trials, studies with other regimens (i.e.
FOLFIRINOX and gemcitabine/Nab-paclitaxel) are
still ongoing and results are pending. There is currently
no role for biologically targeted or biomarker-oriented
therapy in the adjuvant setting [33]. Even though pre-
liminary reports have suggested that expression of the
drug-transporter, hENT1 may be predictive for the
benefit of gemcitabine-based CTx [34], technical prob-
lems with the commercially available antibodies pre-
clude their use in clinical practice.
A major confounding factor is the rate and definition
of R0 resection, which has a large impact on prognosis
[35e38]. Whereas a clearly significant benefit of adju-
vant CTx after R0 resection has been shown in subgroup
analyses for overall survival with hazard ratios of 0.59
(standard deviation (SD): 0.11 with 5-FU), 0.76 (95% CI
of 0.60e0.98 with gemcitabine) and 0.68 (95% CI
0.49e0.93 with gemcitabine/capecitabine) in the three
largest trials, the benefit of postoperative therapy is
more controversial after a R1 resection with hazard
ratios of 0.99, 0.66 (95% CI of 0.39e1.13) and 0.90 (95%
CI 0.72e1.13), respectively [4,31,32,36].
Two competing definitions of R0/R1 are currently
used [38]. The International Union Against Cancer
(UICC) distinguishes microscopically negative resec-
tion margins (R0) from ‘the presence of residual
tumour after treatment’ (R1) which is usually defined
as one or more tumour cells on the immediate resection
margin (0 mm rule). In contrast, the British Royal
College of Pathology (RCPath) defines R1 as the
presence of tumour cells within 1 mm of the resection
margin which leads to a 1.3e1.8 fold higher rate of
resections classified as R1 [39,40]. The rate of R1 re-
sections increases even further if all margins of the
resected specimen are systematically stained, axially
sliced and thoroughly investigated [37,41], a technique
which is only inconsistently followed in clinical practice
[42]. In a recent meta-analysis, R1 resection rates were
28% if a 0-mm margin rule was used, 51% with any
slicing technique and a 1 mm-margin minimum, and
71% with an axial slicing technique and a 1 mm-margin
minimum [37]. Five-year survival rates for ‘R0’ resected
patients accordingly increase from 20.4% to 30.1% and
37.7% [38].
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criteria for the definition of the R0 resection status
(77%), with 89% requesting multicolour staining of the
resection margins by the surgeon [40]. A practical sug-
gestion is that any pathology report should clearly
indicate the definition and give both versions: R1 ac-
cording to UICC (i.e. R1-direct with a minimum margin
of 0 mm), and R1 according to RCPath (i.e. R1< 1 mm
with a margin of 1 mm). If reporting only one, each
study must state which definition is being used.
6. Neoadjuvant treatment in resectable or BR tumours
Neoadjuvant CTx and/or RCTx have the potential to
improve surgical outcome. Several small phase II trials
have suggested increased R0 resection rates and a
promising effect on overall survival with multimodal
therapy. The heterogeneity of trials limits the power of
any conclusion [8], but two meta-analyses and a recent
propensity score matched analysis of the US National
Cancer Database suggested positive effects not only in
BR tumours where secondary resection after downsizing
might be an option but also in those tumours that
appear to be resectable upfront [43e45].
When asked if patients with resectable tumours
should receive neoadjuvant treatment, none of the panel
members were in favour of this approach with all pro-
ceeding directly to resection. Several randomised trials
which address this question have recently started accrual
(e.g. AIOdNCT02047513; Alliance for Clinical
Trials in OncologydNCT02839343, UNICANCERd
NCT02959879, NCT01900327, NCT02172976).
The general concept of ‘borderline-resectable’
tumours to highlight the potential for preoperative
therapy was accepted by a majority (62%, with a number
of abstentions) of the panel.
The most widely propagated definition of BR is
provided by the National Comprehensive CancerTable 2
Criteria defining resectability status according to the NCCN Guidelines (V
Resectability
status
Resectable Borderline-resectable
Vessels defining resectability status
Arterial
CA No s.t.c. s.t.c.  180 or s.t.c. > 180
w/o involvement of aorta
and GDA
SMA No s.t.c. s.t.c.  180
CHA No s.t.c. s.t.c. w/o extension to CA
or HA bifurcation
Venous
SMV/PV No s.t.c. or 180
w/o contour
irregularity
s.t.c.  180 with contour irreg.
or s.t.c. > 180
IVC No s.t.c. s.t.c.
CA, coeliac artery; CHA, common hepatic artery; GDA, gastroduodena
advances rectal cancer; PV, portal vein; SMA, superior mesenteric artery;Network (NCCN) guidelines [7] which have also been
adopted in Europe [8]. Briefly, any direct contact of
the tumour with major arterial vessels but with less
than 180 encasement or obvious involvement of the
superior mesenteric or portal vein (for details see
Table 2) is considered as BR. In contrast, major
(>180) involvement of the arteries or unreconstruc-
tible venous involvement is classified as unresectable
LAPC. Even though this definition was judged as
acceptable by a majority of voting panel members
(50% abstentions; of the remaining panellists, 60%
were in favour), most panellists would not consider
the tumour to be classified as BR if there was only
venous involvement (88% of those voting) and also
were not decided as to its value for arterial involve-
ment (50/50). In summary, the vast majority did not
consider the NCCN definition to be the optimal
discriminator for preoperative therapy. The main
reason for this ambiguity was the potential discrep-
ancy between technical feasibility and oncologic
reasoning. Most of the panellists consider vessel
involvement as a technical hurdle which primarily
impacts surgical morbidity (75%), whereas the general
concept of BR was felt to be oriented towards the
improvement of oncological outcome (78%) through
identification of a subgroup of patients who are in
need of additional treatment.
If neoadjuvant treatment is considered as an option,
chemotherapy (79%) with FOLFIRINOX (100%) was
preferred. Alternatively, induction chemotherapy fol-
lowed by RCTx was the favoured approach for 21% of
the panel members. Ideally RTx should be intensity
modulated (73%) with a fluoropyrimidine (100%) added
as a radiosensitizer. In any case, a pathological diag-
nosis was considered mandatory before the start of
multimodal treatment for 92% of panel members. If this
was not possible, 88% would proceed directly to surgical
exploration and omit preoperative therapy.ersion 2.2016) and Evans et al. (Ann Surg Oncol 2015).
LARC type A (may be
considered for resection
after neoadjuvant Tx)
LARC type B (not
considered for resection)
s.t.c. > 180 amenable to
resection, w/o involvement of
aorta
s.t.c. > 180 with involvement of
the aorta
s.t.c. > 180 but 270 s.t.c. > 270 or 1st jejunal branch
s.t.c > 180 with extention to
CA amenable to reconstruction
>180 with extension beyond
Bifurcation of proper HA
Unreconstructable or s.t.c. with
most proximal jejunal branch
l artery; HA, hepatic artery; IVC, inferior vena cava; LARC, locally
SMV, superior mesenteric vein; s.t.c, solid tumour contact.
M.P. Lutz et al. / European Journal of Cancer 79 (2017) 41e49 47Restaging after preoperative treatment should
include CT and/or MRI (54% CT, 8% MRI and 31%
both) for optimal treatment planning, knowing that
assessment of the treatment response by imaging is
notoriously difficult in this patient population [6]. Serial
measurements of CA 19-9 may be used to exclude pro-
gression but this has never been validated prospectively
[46e48]. Therefore, all such patients without progres-
sion on radiologic imaging should undergo either
exploratory laparotomy (57%) or at least restaging
laparoscopy with the option for open surgical explora-
tion if deemed appropriate (additional 43%).7. Locally advanced disease
Patients with unresectable localised tumours without
distant metastases (LAPC) are commonly considered as
incurable. Systemic chemotherapy is widely used with a
palliative treatment goal. If patients present with stable
disease after 6 months of CTx, sequential RCTx is
sometimes considered an option [12], with the aim to
increase local control [10]. The addition of radiation
therapy to chemotherapy, however is not supported by a
recent European phase III trial, which did not demon-
strate any overall survival benefit [49].
Of note, CTx as well as CRTx occasionally result in
objective or even complete responses in individual patients
which may render the tumour resectable [10,50,51]. In a
recent patient-level meta-analysis, the pooled resectability
rate after CTx for LAPC was 28% after FOLFIRINOX
with R0 resections reported in 74% of the patients. There
appears to be a subgroup of patients whodwhen
responsive to systemic therapydmay technically be
considered for resection. A first definition of this group
was recently proposed by Evans et al. [10], again based on
cross-sectional imaging at the time of diagnosis and the
extent of vessel involvement (Table 2). The resulting
concept separates BR tumours (which are technically
resectable but might profit from additional neoadjuvant
treatment to improve oncologic outcome) from a group of
LAPCwhich are technically unresectable upfront butmay
become ‘potentially resectable after response’ (i.e. LAPC
A according to Evans et al.) and from another group
which will not be resectable (LAPC B).
The distinction of LAPC A from BR was considered
useful by all panel members. Their recommendations for
the primary approach matched those for BR tumours.
CTx (67%) was the preferred option (CRTx suggested
by 8%, sequential CTx-CRTx by 25%). Surgical explo-
ration was recommended in all patients with response
(100%) but also in patients with stable disease (58%).8. Conclusion
In conclusion, standardised cross-sectional imaging was
considered mandatory for any treatment decision. Basedon vessel involvement, the panel distinguished four
groups of patients with different treatment strategies.
Those with a potential for primary R0 resection have to
be separated from patients with either
BR tumoursdwhere resection is technically feasible but
more likely to yield R1 resectionsdand from two
groups of locally advanced tumours (LAPC) which
include either patients might become technically resect-
able after downsizing (LAPC type A) or those who are
definitely inoperable (LAPC type B). In clinical practice,
the first group (resectable) would be directly referred to
surgery, followed by postoperative CTx to improve
overall survival. Neoadjuvant therapy clearly has the
potential to further improve long-term results, especially
in BR tumours, even though there currently is no
evidence-based role for a combined approach outside of
a clinical trial.
Addendum
For additional information, including site live lectures
and discussions, please refer to: www.oncoconferences.
ch/gicc16.
http://web.oncoletter.ch/kongressberichte-live-
webcasts/id-3rd-gastrointestinal-cancer-conference.
html.
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